Ixekizumab

Regimen above is for plaque psoriasis in adults. Psoriatic arthritis: 160 mg (two 80 mg injections) at week 0, then 80 mg every 4 weeks; for psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis the dosing regimen is the same as for plaque psoriasis. Axial spondyloarthritis (radiographic and non-radiographic): 160 mg (two 80 mg injections) at week 0, then 80 mg every 4 weeks. For all indications consider discontinuing treatment in patients who have shown no response after 16 to 20 weeks; some initially partial responders may improve beyond 20 weeks. Elderly: no dose adjustment aged 65 years and over (limited information in those 75 years and over). Paediatric plaque psoriasis (6 years and above) is dosed by weight band, not per kg: greater than 50 kg — starting dose 160 mg (two 80 mg injections) at week 0 then 80 mg every 4 weeks; 25 to 50 kg — starting dose 80 mg at week 0 then 40 mg every 4 weeks. Where no 40 mg presentation is available, 40 mg doses must be prepared and administered by a qualified healthcare professional using the 80 mg pre-filled syringe; use the 80 mg pre-filled pen only in children requiring an 80 mg dose. Not recommended in children with body weight below 25 kg; no relevant use below 25 kg or below 6 years, and efficacy/safety data are not available below 6 years. Paediatric body weights must be recorded and regularly re-checked prior to dosing. Safety and efficacy in paediatric psoriatic arthritis (2 to less than 18 years) have not been established. Subcutaneous use; injection sites may be alternated and areas of psoriatic skin avoided; the solution/pen must not be shaken. Patients may self-inject after proper training if the healthcare professional determines it appropriate. Intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of the indicated conditions.